Teva Pharmaceutical Industries Limited (TEVA)
- Previous Close
16.87 - Open
17.12 - Bid 16.71 x 1300
- Ask 16.99 x 3100
- Day's Range
16.75 - 17.20 - 52 Week Range
12.47 - 22.80 - Volume
8,586,595 - Avg. Volume
12,736,864 - Market Cap (intraday)
19.574B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-1.15 - Earnings Date Jul 29, 2025 - Aug 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 27, 2017
- 1y Target Est
22.88
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
www.tevapharm.com37,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: TEVA
View More
Performance Overview: TEVA
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TEVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TEVA
View MoreValuation Measures
Market Cap
19.50B
Enterprise Value
34.74B
Trailing P/E
--
Forward P/E
6.49
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.16
Price/Book (mrq)
3.10
Enterprise Value/Revenue
2.09
Enterprise Value/EBITDA
23.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.74%
Return on Assets (ttm)
5.27%
Return on Equity (ttm)
-19.11%
Revenue (ttm)
16.62B
Net Income Avi to Common (ttm)
-1.29B
Diluted EPS (ttm)
-1.15
Balance Sheet and Cash Flow
Total Cash (mrq)
1.7B
Total Debt/Equity (mrq)
270.20%
Levered Free Cash Flow (ttm)
1.66B
Research Analysis: TEVA
View MoreResearch Reports: TEVA
View MoreRaising target to $22
Teva Pharmaceutical Industries Ltd. is the world's largest generic pharmaceutical manufacturer, with roughly 76 billion tablets and capsules produced annually. The company has roughly 37,000 employees and over 53 manufacturing facilities across more than 33 countries. One of every 12 prescriptions in the U.S. is filled with Teva products.
RatingPrice TargetStocks are mixed at Tuesday midday with the Nasdaq up more than 1%
Stocks are mixed at Tuesday midday with the Nasdaq up more than 1% while the Dow is lower. Inflation slowed last month in the first measure showing the possible impact of President Trump's tariffs. CPI came in at 2.3% for April year-over-year compared to 2.4% in March. On a month-over-month basis, prices increased 0.2%, above the 0.1% decrease seen in March but lower than the 0.3% expected by economists. Core CPI was 2.8% for April matching March. The yield on the 10-year Treasury note is 4.47%. Oil is up 1% at $63 per barrel.
Daily – Vickers Top Buyers & Sellers for 05/13/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice Target